Gilead Sciences (NasdaqGS:GILD) has been the center of investor activism, facing several shareholder proposals, including the ...

News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...

The Role of Lenacapavir According to a PTI report, the injection contains a drug called Lenacapavir, developed by Gilead Sciences, a US-based biopharmaceutical company. Lenacapavir blocks HIV from ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.

Citigroup said it’s “very bullish” on Gilead’s HIV franchise, arguing it’s the drugmaker’s biggest value driver as the company’s new ...

Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is ...

Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

Winnie Byanyima, head of UNAIDS, criticized the impact of reduced U.S. funding in combatting HIV. She proposed a deal to U.S.

Gilead Sciences recently experienced a significant ... highlighted by successful data presentations at CROI 2025. The approval of lenacapavir for multi-drug resistant HIV and its promising trial ...

Gilead Sciences. “Once-yearly lenacapavir, if approved, could become an important new HIV prevention option that could help address PrEP adherence and persistence challenges for individuals who ...

The head of the U.N. AIDS agency says Donald Trump should enable the American company Gilead to roll out its prevention drug ...